Discovery and structure-activity relationship studies of a novel and specific peptide motif, Pro-X-X-X-Asp-X, as a platelet fibrinogen receptor antagonist

被引:14
作者
Hayashi, Y [1 ]
Katada, J [1 ]
Sato, Y [1 ]
Igarashi, K [1 ]
Takiguchi, Y [1 ]
Harada, T [1 ]
Muramatsu, M [1 ]
Yasuda, E [1 ]
Uno, I [1 ]
机构
[1] Nippon Steel Corp Ltd, Adv Technol Res Labs, Life Sci Res Ctr, Nakahara Ku, Kawasaki, Kanagawa 211, Japan
关键词
fibrinogen receptor antagonist; integrins; peptide motif; RGD peptide; anti-platelet agent;
D O I
10.1016/S0968-0896(97)10050-5
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A novel hexapeptide, H-Pro-Ser-Nva-Gly-Asp-Trp-OH 6, a specific antagonist of platelet fibrinogen receptor (GpIIb/IIIa), was discovered in a structure-activity relationship (SAR) study where the role of the N-terminal Pro moiety of an RGD-containing peptide, H-Pro-Ser-Arg-Gly-Asp-Trp-OH 1, which is a potent but not specific antagonist toward GpIIb/IIIa integrin, was investigated. This novel peptide 6 exhibits very high activity as a human platelet aggregation inhibitor (IC50 0.59 mu M, human PRP/collagen) as well as marked specificity for GpIIb/IIIa. A series of substitutions at the third position (Nva residue) in this hexapeptide, focused on the conformational rigidity, led to compounds which are superior to the original novel peptide 6 with regard to anti-platelet activity. The peptides, H-Pro-Ser-Hyp-Gly-Asp-Trp-OH 17 and H-Pro-Ser-Delta Pro-Gly-Asp-Trp-OH 18 with the 5-membered ring structure, which restricted the conformation of the peptide backbone at the third position, inhibited the aggregation of human platelets at submicromolar concentrations (IC50 0.39 and 0.30 mu M, respectively). Further structure-activity relationship studies at each position of the peptide sequence suggest a novel motif sequence, Pro-X1-X2-X3-Asp-X4, for specific GpIIb/IIIa integrin recognition, in which the N-terminal free Pro residue and the Asp residue at the fifth position are essential to the activity. This motif sequence is summarized as follows: (1) a small amino acid such as Ser, Ala or Gly is preferable at X1 position; (2) X2 may be any amino acid, preferably a bulky amino acid such as Tie or a cyclic amino acid such as Pro; (3) X3 must be a small amino acid such as Gly; and (4) X4 is preferably an amino acid with an aromatic side chain. (C) 1998 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:355 / 364
页数:10
相关论文
共 43 条
[1]   PLATELETS AND EXTRACORPOREAL-CIRCULATION [J].
ADDONIZIO, VP ;
COLMAN, RW .
BIOMATERIALS, 1982, 3 (01) :9-15
[2]   SOLUTION STRUCTURE OF KISTRIN, A POTENT PLATELET-AGGREGATION INHIBITOR AND GP-IIB-IIIA ANTAGONIST [J].
ADLER, M ;
LAZARUS, RA ;
DENNIS, MS ;
WAGNER, G .
SCIENCE, 1991, 253 (5018) :445-448
[3]  
Atherton E., 1989, SOLID PHASE PEPTIDE
[4]  
Austel Volkhard, 1994, Drugs of the Future, V19, P757
[5]   PROTON NMR ASSIGNMENTS AND SECONDARY STRUCTURE OF THE SNAKE-VENOM PROTEIN ECHISTATIN [J].
CHEN, Y ;
PITZENBERGER, SM ;
GARSKY, VM ;
LUMMA, PK ;
SANYAL, G ;
BAUM, J .
BIOCHEMISTRY, 1991, 30 (50) :11625-11636
[6]   DESIGN AND SYNTHESIS OF NOVEL CYCLIC RGD-CONTAINING PEPTIDES AS HIGHLY POTENT AND SELECTIVE INTEGRIN ALPHA(IIB)BETA(3) ANTAGONISTS [J].
CHENG, S ;
CRAIG, WS ;
MULLEN, D ;
TSCHOPP, JF ;
DIXON, D ;
PIERSCHBACHER, MD .
JOURNAL OF MEDICINAL CHEMISTRY, 1994, 37 (01) :1-8
[7]  
COLLEN D, 1994, THROMB HAEMOSTASIS, V71, P95
[8]   PLATELETS AND THROMBOLYTIC THERAPY [J].
COLLER, BS .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 322 (01) :33-42
[9]  
Cook Nigel S., 1994, Drugs of the Future, V19, P135
[10]  
COOK NS, 1993, THROMB HAEMOSTASIS, V70, P838